Approximately 85% of women carrying TP53 mutations eventually develop breast cancer, either due to germline (5–8%) or somatic (37%) mutations; these mutations predominate in triple-negative, HER2-enriched, and basal-like breast cancers, and they are usually located in exons 5–8 [126]. Here, ERBB2 is linked to breast cancer.